• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will COO’s CooperSurgical Exit Talks and Asia-Pacific Slowdown Reshape Cooper Companies' (COO) Narrative?

    Simply Wall St·06/16/2026 13:28:43
    Listen to the news
    • Earlier this month, The Cooper Companies reported second-quarter 2026 results showing sales rising to US$1,081.5 million from US$1,002.3 million a year earlier, but swinging from net income of US$87.7 million to a net loss of US$77.9 million and issuing updated full-year 2026 revenue guidance of US$4.285 billion to US$4.321 billion.
    • At the same time, Cooper confirmed it is in advanced discussions to sell its CooperSurgical business, while continuing share repurchases that have retired 5.17% of outstanding stock since 2011, pointing to an active reshaping of its portfolio and capital allocation priorities.
    • We’ll now examine how the softer CooperVision outlook in Asia-Pacific, alongside the potential CooperSurgical divestiture, reshapes Cooper’s investment narrative.

    Find 47 companies with promising cash flow potential yet trading below their fair value.

    Cooper Companies Investment Narrative Recap

    To own Cooper Companies today, you need to believe in the long term value of its contact lens and women’s health franchises while accepting some near term earnings noise. The latest quarter’s swing to a net loss and trimmed 2026 revenue outlook highlight how softer Asia Pacific demand and portfolio changes could affect the key short term catalyst: stabilizing CooperVision growth. The biggest current risk is that pricing pressure and weaker APAC trends persist, muting the benefit of its premium lens rollout.

    The most relevant recent development is Cooper’s confirmation that it is in advanced talks to sell CooperSurgical. If completed, that move would concentrate the business in CooperVision just as guidance was lowered for that segment, tying the share price narrative even more tightly to how well MyDAY and other premium lenses offset Asia Pacific softness and any remaining volatility in older product lines.

    Yet beneath that potential upside, there is a real risk investors should be aware of around Asia Pacific pricing pressure and slower contact lens mix improvement...

    Read the full narrative on Cooper Companies (it's free!)

    Cooper Companies' narrative projects $4.9 billion revenue and $829.7 million earnings by 2029. This requires 5.4% yearly revenue growth and an earnings increase of about $428 million from $401.4 million today.

    Uncover how Cooper Companies' forecasts yield a $87.14 fair value, a 29% upside to its current price.

    Exploring Other Perspectives

    COO 1-Year Stock Price Chart
    COO 1-Year Stock Price Chart

    The most pessimistic analysts were already assuming only about 4.5% annual revenue growth and US$808.6 million of earnings by 2029, so this weaker APAC update could reinforce their concern that premium lens momentum and mix shift might not be enough on its own, underscoring how differently you and other shareholders might view Cooper’s prospects.

    Explore 5 other fair value estimates on Cooper Companies - why the stock might be worth as much as 89% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    • Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
    • Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.